Bicycle Therapeutics (BCYC) Cash & Equivalents (2018 - 2026)

Bicycle Therapeutics (BCYC) has 9 years of Cash & Equivalents data on file, last reported at $559.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 29.44% year-over-year to $559.5 million; the trailing twelve-month figure through Mar 2026 stood at $559.5 million (down 29.44% YoY), and the FY2025 full-year result was $628.1 million, down 5.53% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $559.5 million, down from $628.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $961.4 million in Q2 2024 and bottomed at $100.0 million in Q1 2022.
• The 5-year median for Cash & Equivalents is $559.5 million (2026), against an average of $543.0 million.
• The widest annual swing landed in 2022, when Cash & Equivalents slumped 48.95%; it then surged 193.81% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $339.2 million in 2022, then jumped by 55.22% to $526.4 million in 2023, then increased by 26.31% to $664.9 million in 2024, then slipped by 5.53% to $628.1 million in 2025, then declined by 10.92% to $559.5 million in 2026.
• The last three Cash & Equivalents figures came in at $559.5 million (Q1 2026), $628.1 million (Q4 2025), and $648.3 million (Q3 2025), per Business Quant data.

Peer Comparison